Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

FERRIS E GEORGE

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1467474080
CMS profile
1059673
Location
ST AUGUSTINE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$3,495.35

106 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,293.08 104
Travel and Lodging $202.27 2

By paying entity

PY2023 · entire year · sorted by reported total

Page 3 of 3; records 101–106 of 106 matching records. This page contains 6 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

FERRIS E GEORGE

NPI 1467474080 · CMS profile ID 1059673

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

ST AUGUSTINE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–106 of 106 matching records. This page contains 6 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1467474080?year=2023&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
FERRIS E GEORGE, NPI 1467474080, CMS profile ID 1059673. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–106 of 106 matching records. This page contains 6 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1467474080?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). FERRIS E GEORGE, NPI 1467474080, CMS profile ID 1059673. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–106 of 106 matching records. This page contains 6 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1467474080?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
FERRIS E GEORGE, NPI 1467474080, CMS profile ID 1059673, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–106 of 106 matching records. This page contains 6 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1467474080?year=2023&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

106 matching records · $3,495.35 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 106 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–106 of 106.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Medtronic, Inc. $6.5901/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025719607 CMS
ShockWave Medical, Inc $35.8501/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058518611 CMS
Novartis Pharmaceuticals Corporation $19.8501/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991987783 CMS
Medtronic, Inc. $6.4701/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025719577 CMS
Medtronic, Inc. $78.3701/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025719595 CMS
Terumo Medical Corporation $12.8501/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056268813 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,528.65 66
PY2020 $1,853.31 59
PY2021 $2,315.14 87
PY2022 $2,587.39 95
PY2023 $3,495.35 106
PY2024 $2,355.66 83
PY2025 $1,939.70 20

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,095,161.68 342
PY2024 Principal investigator $1,080,208.21 21
PY2023 Principal investigator $608,681.91 88
PY2022 Principal investigator $583,278.26 18
PY2021 Principal investigator $181,180.55 19
PY2020 Principal investigator $95,411.78 16
PY2019 Principal investigator $108,783.98 42

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

342 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $20,790.00 12/19/2025 Non-covered Recipient Entity
ECIR MEDICAL COMMUNICATIONS
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event No dispute reported 06/30/2026 1185542262
Principal investigator 1 Boehringer Ingelheim International GmbH $259.74 12/17/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220767551
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 12/17/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220767553
Principal investigator 1 Boehringer Ingelheim International GmbH $59.94 12/17/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220767555
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $25,012.00 12/17/2025 Non-covered Recipient Entity
ECIR Intermediate II LLC
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220815129
Principal investigator 1 Boehringer Ingelheim International GmbH $543.00 12/15/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621632
Principal investigator 1 Boehringer Ingelheim International GmbH $3,293.00 12/15/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621634
Principal investigator 1 Boehringer Ingelheim International GmbH $543.00 12/15/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621636
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $10,052.10 12/15/2025 Non-covered Recipient Entity
East Coast Institute For Research-Jacksonville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220818584
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $624.00 12/15/2025 Non-covered Recipient Entity
East Coast Institute For Research-Jacksonville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220818586
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $375.00 12/15/2025 Non-covered Recipient Entity
East Coast Institute For Research-Jacksonville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220818588
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1,669.24 12/03/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220998259
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 12/01/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621628
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 12/01/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621630
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728655
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728657
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728659
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728661
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728663
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728665
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220767549
Principal investigator 1 Boehringer Ingelheim International GmbH $455.00 11/19/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621616
Principal investigator 1 Boehringer Ingelheim International GmbH $1,701.00 11/19/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621618
Principal investigator 1 Boehringer Ingelheim International GmbH $3,293.00 11/19/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621620
Principal investigator 1 Boehringer Ingelheim International GmbH $3,293.00 11/19/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621622
Principal investigator 1 Boehringer Ingelheim International GmbH $3,434.00 11/19/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621624
Principal investigator 1 Boehringer Ingelheim International GmbH $2,492.00 11/19/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621626
Principal investigator 1 Boehringer Ingelheim International GmbH $292.00 11/19/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728667
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $10,883.70 11/13/2025 Non-covered Recipient Entity
East Coast Institute For Research-Jacksonville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220818582
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,338.48 11/11/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220994067
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 11/05/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220808222
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 11/01/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621612
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 11/01/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621614
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728643
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728645
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728647
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728649
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728651
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728653
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220767547
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,097.00 10/28/2025 Non-covered Recipient Entity
East Coast Institute For Research-Jacksonville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220818572
Principal investigator 1 Boehringer Ingelheim International GmbH $799.20 10/27/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621638
Principal investigator 1 Boehringer Ingelheim International GmbH $401.50 10/27/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621640
Principal investigator 1 Boehringer Ingelheim International GmbH $4.70 10/27/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621642
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $391.52 10/23/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220814219
Principal investigator 1 Novartis Pharmaceuticals Corporation $13,500.00 10/23/2025 Non-covered Recipient Entity
Ecir Parent Llc
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190305033
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $8,346.20 10/22/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220994065
Principal investigator 1 Boehringer Ingelheim International GmbH $455.00 10/20/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621574
Principal investigator 1 Boehringer Ingelheim International GmbH $543.00 10/20/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621576
Principal investigator 1 Boehringer Ingelheim International GmbH $543.00 10/20/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621578
Principal investigator 1 Boehringer Ingelheim International GmbH $3,888.00 10/20/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621580
Principal investigator 1 Boehringer Ingelheim International GmbH $3,293.00 10/20/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621582
Principal investigator 1 Boehringer Ingelheim International GmbH $543.00 10/20/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621584
Principal investigator 1 Boehringer Ingelheim International GmbH $543.00 10/20/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621586
Principal investigator 1 Boehringer Ingelheim International GmbH $543.00 10/20/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621588
Principal investigator 1 Boehringer Ingelheim International GmbH $543.00 10/20/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621590
Principal investigator 1 Boehringer Ingelheim International GmbH $3,538.00 10/20/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621592
Principal investigator 1 Boehringer Ingelheim International GmbH $3,800.00 10/20/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621594
Principal investigator 1 Boehringer Ingelheim International GmbH $543.00 10/20/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621596
Principal investigator 1 Boehringer Ingelheim International GmbH $455.00 10/20/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621598
Principal investigator 1 Boehringer Ingelheim International GmbH $455.00 10/20/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621600
Principal investigator 1 Boehringer Ingelheim International GmbH $1,701.00 10/20/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621602
Principal investigator 1 Boehringer Ingelheim International GmbH $543.00 10/20/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621604
Principal investigator 1 Boehringer Ingelheim International GmbH $403.00 10/20/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621606
Principal investigator 1 Boehringer Ingelheim International GmbH $1,701.00 10/20/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621608
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 10/03/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621568
Principal investigator 1 Boehringer Ingelheim International GmbH $600.00 10/03/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621570
Principal investigator 1 Boehringer Ingelheim International GmbH $452.00 10/02/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621572
Principal investigator 1 Boehringer Ingelheim International GmbH $1,000.00 10/02/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621610
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 10/01/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621564
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 10/01/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621566
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728631
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728633
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728635
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728637
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728639
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728641
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220767545
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,101.00 10/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-Jacksonville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220818580
Principal investigator 1 Boehringer Ingelheim International GmbH $1,000.00 09/24/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621486
Principal investigator 1 Boehringer Ingelheim International GmbH $112.00 09/24/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621488
Principal investigator 1 Boehringer Ingelheim International GmbH $350.00 09/24/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621490
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 09/24/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621492
Principal investigator 1 Boehringer Ingelheim International GmbH $78.00 09/24/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621494
Principal investigator 1 Boehringer Ingelheim International GmbH $650.00 09/24/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621496
Principal investigator 1 Boehringer Ingelheim International GmbH $375.00 09/24/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621498
Principal investigator 1 Boehringer Ingelheim International GmbH $94.00 09/24/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621500
Principal investigator 1 Boehringer Ingelheim International GmbH $280.00 09/24/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621502
Principal investigator 1 Boehringer Ingelheim International GmbH $1,000.00 09/24/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621504
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,949.20 09/18/2025 Non-covered Recipient Entity
East Coast Institute For Research-Jacksonville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220818578
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $391.52 09/12/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220814217
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,338.48 09/03/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220994079
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 09/01/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621474
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 09/01/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621480
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728557
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728559
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728561
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728593
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728605
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728607
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220767539
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $6,676.96 08/29/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220998257
Principal investigator 1 Boehringer Ingelheim International GmbH $328.50 08/26/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728623
Principal investigator 1 Boehringer Ingelheim International GmbH $259.74 08/26/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220767541
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 08/26/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220767543
Principal investigator 1 Boehringer Ingelheim International GmbH $3,041.00 08/20/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621506
Principal investigator 1 Boehringer Ingelheim International GmbH $452.00 08/20/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621538
Principal investigator 1 Boehringer Ingelheim International GmbH $452.00 08/20/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621540
Principal investigator 1 Boehringer Ingelheim International GmbH $3,041.00 08/20/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621542
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $8,346.20 08/14/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220994063
Principal investigator 1 AstraZeneca Pharmaceuticals LP $39,845.00 08/07/2025 Non-covered Recipient Entity
ECIR MEDICAL COMMUNICATIONS
a phase third,randomised,double blind,placebo controlled,eventdriven study to evaluate the effect of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on the risk of incident heart failure and cardiovascular death in participants with increased risk of reveloping heart failure No dispute reported 06/30/2026 1185542264
Principal investigator 1 Boehringer Ingelheim International GmbH $954.00 08/07/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621508
Principal investigator 1 Boehringer Ingelheim International GmbH $1,422.00 08/07/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621510
Principal investigator 1 Boehringer Ingelheim International GmbH $95.00 08/07/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621512
Principal investigator 1 Boehringer Ingelheim International GmbH $1,232.00 08/07/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621514
Principal investigator 1 Boehringer Ingelheim International GmbH $560.00 08/07/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621516
Principal investigator 1 Boehringer Ingelheim International GmbH $59.00 08/07/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621518
Principal investigator 1 Boehringer Ingelheim International GmbH $345.00 08/07/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621520
Principal investigator 1 Boehringer Ingelheim International GmbH $138.00 08/07/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621522
Principal investigator 1 Boehringer Ingelheim International GmbH $69.00 08/07/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621524
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 08/07/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621526
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 08/07/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621528
Principal investigator 1 Boehringer Ingelheim International GmbH $1,839.00 08/07/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621530
Principal investigator 1 Boehringer Ingelheim International GmbH $1,750.00 08/07/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621532
Principal investigator 1 Boehringer Ingelheim International GmbH $220.00 08/07/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621534
Principal investigator 1 Boehringer Ingelheim International GmbH $156.00 08/07/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621536
Principal investigator 1 Boehringer Ingelheim International GmbH $1,470.00 08/07/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621544
Principal investigator 1 Boehringer Ingelheim International GmbH $2,400.00 08/07/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621546
Principal investigator 1 Boehringer Ingelheim International GmbH $60.00 08/07/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621548
Principal investigator 1 Boehringer Ingelheim International GmbH $76.00 08/07/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621550
Principal investigator 1 Boehringer Ingelheim International GmbH $38.00 08/07/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621552
Principal investigator 1 Boehringer Ingelheim International GmbH $450.00 08/07/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621554
Principal investigator 1 Boehringer Ingelheim International GmbH $80.00 08/07/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621556
Principal investigator 1 Boehringer Ingelheim International GmbH $378.00 08/07/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621558
Principal investigator 1 Boehringer Ingelheim International GmbH $190.00 08/07/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621560
Principal investigator 1 Boehringer Ingelheim International GmbH $112.00 08/07/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621562
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $14,994.90 08/06/2025 Non-covered Recipient Entity
East Coast Institute For Research-Jacksonville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220818564
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 08/01/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621476
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 08/01/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621478
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728595
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728597
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728599
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728601
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728603
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728619
Principal investigator 1 Boehringer Ingelheim International GmbH $30.79 08/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728621
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 08/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220767531
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 08/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220767533
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220767535
Principal investigator 1 Boehringer Ingelheim International GmbH $23.75 08/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220767537
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $11,125.00 08/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-Jacksonville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220818560
Principal investigator 1 Boehringer Ingelheim International GmbH $3,739.00 07/25/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621460
Principal investigator 1 Boehringer Ingelheim International GmbH $3,041.00 07/25/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621462
Principal investigator 1 Boehringer Ingelheim International GmbH $1,701.00 07/25/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621464
Principal investigator 1 Boehringer Ingelheim International GmbH $1,701.00 07/25/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621466
Principal investigator 1 Boehringer Ingelheim International GmbH $455.00 07/25/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621468
Principal investigator 1 Boehringer Ingelheim International GmbH $252.00 07/25/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621470
Principal investigator 1 Boehringer Ingelheim International GmbH $104.00 07/25/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621472
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,407.90 07/19/2025 Non-covered Recipient Entity
East Coast Institute For Research-Jacksonville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220818558
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $375.00 07/16/2025 Non-covered Recipient Entity
East Coast Institute For Research-Jacksonville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220818552
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,720.00 07/16/2025 Non-covered Recipient Entity
East Coast Institute For Research-Jacksonville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220818554
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $500.00 07/16/2025 Non-covered Recipient Entity
East Coast Institute For Research-Jacksonville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220818556
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,504.50 07/14/2025 Non-covered Recipient Entity
East Coast Institute for Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215513583
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 07/01/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621482
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 07/01/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621484
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728609
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728611
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728613
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728615
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728617
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 07/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728625
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 07/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728627
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 07/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728629
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,338.48 06/25/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220994077
Principal investigator 1 Boehringer Ingelheim International GmbH $81.62 06/24/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621452
Principal investigator 1 Boehringer Ingelheim International GmbH $328.50 06/24/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621454
Principal investigator 1 Boehringer Ingelheim International GmbH $3.48 06/24/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621456
Principal investigator 1 Boehringer Ingelheim International GmbH $3.76 06/24/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621458
Principal investigator 1 Boehringer Ingelheim International GmbH $455.00 06/20/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621434
Principal investigator 1 Boehringer Ingelheim International GmbH $455.00 06/20/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621436
Principal investigator 1 Boehringer Ingelheim International GmbH $452.00 06/20/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621438
Principal investigator 1 Boehringer Ingelheim International GmbH $452.00 06/04/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621414
Principal investigator 1 Boehringer Ingelheim International GmbH $1,701.00 06/04/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621416
Principal investigator 1 Boehringer Ingelheim International GmbH $455.00 06/04/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621418
Principal investigator 1 Boehringer Ingelheim International GmbH $455.00 06/04/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621420
Principal investigator 1 Boehringer Ingelheim International GmbH $3,041.00 06/04/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621422
Principal investigator 1 Boehringer Ingelheim International GmbH $3,041.00 06/04/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621424
Principal investigator 1 Boehringer Ingelheim International GmbH $455.00 06/04/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621426
Principal investigator 1 Boehringer Ingelheim International GmbH $1,701.00 06/04/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621428
Principal investigator 1 Boehringer Ingelheim International GmbH $3,041.00 06/04/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621430
Principal investigator 1 Boehringer Ingelheim International GmbH $452.00 06/04/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621432
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 06/01/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621410
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 06/01/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621412
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 06/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728535
Principal investigator 1 Boehringer Ingelheim International GmbH $21.50 06/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728537
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 06/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728539
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728541
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728543
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728577
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728579
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728581
Principal investigator 1 Boehringer Ingelheim International GmbH $839.16 05/27/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621444
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 05/27/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621446
Principal investigator 1 Boehringer Ingelheim International GmbH $2.61 05/27/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621448
Principal investigator 1 Boehringer Ingelheim International GmbH $1.88 05/27/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621450
Principal investigator 1 Boehringer Ingelheim International GmbH $128.26 05/27/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728551
Principal investigator 1 Boehringer Ingelheim International GmbH $693.50 05/27/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728553
Principal investigator 1 Boehringer Ingelheim International GmbH $27.60 05/27/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728555
Principal investigator 1 Boehringer Ingelheim International GmbH $199.80 05/27/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728589
Principal investigator 1 Boehringer Ingelheim International GmbH $29.58 05/27/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728591
Principal investigator 1 Boehringer Ingelheim International GmbH $375.00 05/09/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621402
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 05/09/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621404
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,858.30 05/09/2025 Non-covered Recipient Entity
East Coast Institute For Research-Jacksonville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220818550
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,338.48 05/08/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220994075
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 05/01/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621406
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 05/01/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621408
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 05/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728525
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728527
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728529
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728531
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728533
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728575
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $875.00 05/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-Jacksonville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220818546
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $900.00 05/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-Jacksonville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220818548
Principal investigator 1 Boehringer Ingelheim International GmbH $455.00 04/25/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621362
Principal investigator 1 Boehringer Ingelheim International GmbH $1,701.00 04/25/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621364
Principal investigator 1 Boehringer Ingelheim International GmbH $1,701.00 04/25/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621366
Principal investigator 1 Boehringer Ingelheim International GmbH $245.00 04/25/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621368
Principal investigator 1 Boehringer Ingelheim International GmbH $3,132.00 04/25/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621370
Principal investigator 1 Boehringer Ingelheim International GmbH $1,701.00 04/25/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621372
Principal investigator 1 Boehringer Ingelheim International GmbH $1,701.00 04/25/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621374
Principal investigator 1 Boehringer Ingelheim International GmbH $1,701.00 04/25/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621376
Principal investigator 1 Boehringer Ingelheim International GmbH $1,701.00 04/25/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621378
Principal investigator 1 Boehringer Ingelheim International GmbH $1,701.00 04/25/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621380
Principal investigator 1 Boehringer Ingelheim International GmbH $1,701.00 04/25/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621382
Principal investigator 1 Boehringer Ingelheim International GmbH $1,701.00 04/25/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621384
Principal investigator 1 Boehringer Ingelheim International GmbH $1,701.00 04/25/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621386
Principal investigator 1 Boehringer Ingelheim International GmbH $199.80 04/23/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621440
Principal investigator 1 Boehringer Ingelheim International GmbH $4.65 04/23/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621442
Principal investigator 1 Boehringer Ingelheim International GmbH $23.32 04/23/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728545
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 04/23/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728547
Principal investigator 1 Boehringer Ingelheim International GmbH $5.22 04/23/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728549
Principal investigator 1 Boehringer Ingelheim International GmbH $99.90 04/23/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728583
Principal investigator 1 Boehringer Ingelheim International GmbH $1,105.50 04/23/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728585
Principal investigator 1 Boehringer Ingelheim International GmbH $13.80 04/23/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728587
Principal investigator 1 Boehringer Ingelheim International GmbH $14,000.00 04/21/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621352
Principal investigator 1 Boehringer Ingelheim International GmbH $78.00 04/21/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621354
Principal investigator 1 Boehringer Ingelheim International GmbH $200.00 04/21/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621356
Principal investigator 1 Boehringer Ingelheim International GmbH $3,024.00 04/21/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621358
Principal investigator 1 Boehringer Ingelheim International GmbH $112.00 04/21/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621360
Principal investigator 1 Boehringer Ingelheim International GmbH $600.00 04/21/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621388
Principal investigator 1 Boehringer Ingelheim International GmbH $2,870.00 04/21/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621390
Principal investigator 1 Boehringer Ingelheim International GmbH $1,365.00 04/21/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621392
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 04/21/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621394
Principal investigator 1 Boehringer Ingelheim International GmbH $112.00 04/21/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621396
Principal investigator 1 Boehringer Ingelheim International GmbH $69.00 04/21/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621398
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 04/21/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621400
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $987.30 04/11/2025 Non-covered Recipient Entity
East Coast Institute For Research-Jacksonville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220818544
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 04/01/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621348
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 04/01/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621350
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728519
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728521
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 04/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728523
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728569
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728571
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728573
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $6,676.96 03/27/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220994073
Principal investigator 1 Boehringer Ingelheim International GmbH $159.84 03/25/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621346
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 03/25/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728515
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $18,407.70 03/24/2025 Non-covered Recipient Entity
East Coast Institute For Research-Jacksonville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220818542
Principal investigator 1 Boehringer Ingelheim International GmbH $455.00 03/19/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621320
Principal investigator 1 Boehringer Ingelheim International GmbH $3,888.00 03/19/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621322
Principal investigator 1 Boehringer Ingelheim International GmbH $3,888.00 03/19/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621324
Principal investigator 1 Boehringer Ingelheim International GmbH $3,888.00 03/19/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621326
Principal investigator 1 Boehringer Ingelheim International GmbH $1,701.00 03/19/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621328
Principal investigator 1 Boehringer Ingelheim International GmbH $452.00 03/19/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621330
Principal investigator 1 Boehringer Ingelheim International GmbH $452.00 03/19/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621332
Principal investigator 1 Boehringer Ingelheim International GmbH $452.00 03/19/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621334
Principal investigator 1 Boehringer Ingelheim International GmbH $3,132.00 03/19/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621336
Principal investigator 1 Boehringer Ingelheim International GmbH $3,132.00 03/19/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621338
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $950.00 03/12/2025 Non-covered Recipient Entity
East Coast Institute For Research-Jacksonville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220818566
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,700.00 03/12/2025 Non-covered Recipient Entity
East Coast Institute For Research-Jacksonville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220818568
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,129.10 03/12/2025 Non-covered Recipient Entity
East Coast Institute For Research-Jacksonville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220818570
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $550.00 03/05/2025 Non-covered Recipient Entity
East Coast Institute For Research-Jacksonville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220818562
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 03/01/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621314
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 03/01/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621316
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728505
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728507
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728509
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 03/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728511
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728565
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728567
Principal investigator 1 Boehringer Ingelheim International GmbH $3,739.00 02/25/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621304
Principal investigator 1 Boehringer Ingelheim International GmbH $312.00 02/25/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621306
Principal investigator 1 Boehringer Ingelheim International GmbH $2,393.00 02/25/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621308
Principal investigator 1 Boehringer Ingelheim International GmbH $81.62 02/25/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728513
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,338.48 02/25/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220994071
Principal investigator 1 Novartis Pharmaceuticals Corporation $465,775.05 02/24/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH LLC
HPS-4/TIMI 65/ORION-4: A Double-blind Randomized Placebo-controlled Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Atherosclerotic Cardiovascular Disease No dispute reported 06/30/2026 1190308984
Principal investigator 1 Boehringer Ingelheim International GmbH $375.00 02/05/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621300
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 02/05/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621302
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,624.00 02/04/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
A multi-center, randomized, double-blind placebo-controlled and open-label active-controlled, parallel-group, 24-week proof of concept and dose-finding study to evaluate efficacy, safety, and tolerability of XXB750 in patients with heart failure No dispute reported 06/30/2026 1190300227
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 02/01/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621310
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 02/01/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621312
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728495
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728497
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728499
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728501
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728503
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 02/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728563
Principal investigator 1 Boehringer Ingelheim International GmbH $210.00 01/31/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621318
Principal investigator 1 Boehringer Ingelheim International GmbH $949.00 01/27/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621340
Principal investigator 1 Boehringer Ingelheim International GmbH $13.92 01/27/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621342
Principal investigator 1 Boehringer Ingelheim International GmbH $19.74 01/27/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621344
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $9,270.00 01/27/2025 Non-covered Recipient Entity
East Coast Institute For Research-Jacksonville
Obesity Long term safety in patients with CV risk No dispute reported 06/30/2026 1220818576
Principal investigator 1 Novartis Pharmaceuticals Corporation $14,263.32 01/27/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH LLC
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190308986
Principal investigator 1 Boehringer Ingelheim International GmbH $3,888.00 01/24/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621288
Principal investigator 1 Boehringer Ingelheim International GmbH $3,132.00 01/24/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621290
Principal investigator 1 Boehringer Ingelheim International GmbH $2,393.00 01/24/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621292
Principal investigator 1 Boehringer Ingelheim International GmbH $3,346.00 01/24/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621294
Principal investigator 1 Boehringer Ingelheim International GmbH $3,888.00 01/22/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621276
Principal investigator 1 Boehringer Ingelheim International GmbH $3,888.00 01/22/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621278
Principal investigator 1 Boehringer Ingelheim International GmbH $3,132.00 01/22/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621280
Principal investigator 1 Boehringer Ingelheim International GmbH $3,132.00 01/22/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621282
Principal investigator 1 Boehringer Ingelheim International GmbH $2,393.00 01/22/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621284
Principal investigator 1 Boehringer Ingelheim International GmbH $3,346.00 01/22/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621286
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $129.00 01/17/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220808220
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,100.00 01/17/2025 Non-covered Recipient Entity
East Coast Institute For Research-Jacksonville
Obesity Long term safety in patients with CV risk No dispute reported 06/30/2026 1220818574
Principal investigator 1 Novartis Pharmaceuticals Corporation $546.79 01/15/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH JACKSONVILLE
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190303697
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $5,007.72 01/10/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220994069
Principal investigator 1 Novartis Pharmaceuticals Corporation $25,752.00 01/07/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190300173
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,023.00 01/07/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190300221
Principal investigator 1 Amgen Inc. $48,360.94 01/06/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH, LLC
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a) No dispute reported 06/30/2026 1246641003
Principal investigator 1 Eli Lilly and Company $5,935.00 01/06/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION AND OBESITY (SUMMIT No dispute reported 06/30/2026 1187880399
Principal investigator 1 AstraZeneca Pharmaceuticals LP $21,166.42 01/03/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH, LLC
A Phase III Randomised Doubleblind Study to Evaluate the Effect of Balcinrenone Dapagliflozin Compared with Dapagliflozin on the Risk of Heart Failure Events and Cardiovascular Death in Patients with Heart Failure and Impaired Kidney Function No dispute reported 06/30/2026 1185542260
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 01/01/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621296
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 01/01/2025 Non-covered Recipient Entity
EAST COAST INST FOR RSRCH LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220621298
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728485
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728487
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728489
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728491
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728493
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 01/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-St Augustine
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728517